9-(4'-dimethylaminophenyl)-2,6,7-trihydroxy-xanthene-3-one is a Potentially Novel Antiplatelet Drug which Antagonizes the Effect of Thromboxane A2
Language English Country Netherlands Media print
Document type Journal Article
PubMed
29032760
DOI
10.2174/1573406413666171010102535
PII: MC-EPUB-86292
Knihovny.cz E-resources
- Keywords
- Antiplatelet, arachidonic acid, cyclooxygenase, platelet, thromboxane, xanthene-3-one,
- MeSH
- Platelet Aggregation drug effects MeSH
- Platelet Aggregation Inhibitors chemical synthesis chemistry pharmacology MeSH
- Humans MeSH
- Molecular Structure MeSH
- Thromboxane A2 antagonists & inhibitors MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Xanthones chemical synthesis chemistry pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- 9-(4'-dimethylaminophenyl)-2,6,7-trihydroxyxanthene-3-one MeSH Browser
- Platelet Aggregation Inhibitors MeSH
- Thromboxane A2 MeSH
- Xanthones MeSH
BACKGROUND: Currently, used oral antiplatelet drugs are both limited and associated with the risk of treatment failure/resistance. Research in this area is hence highly desired. A series of xanthene-3-ones derivatives, we had synthesized, showed us that these derivatives had antiplatelet activity. As far as we know, no research on the effects of xanthen-3-ones in this area has been done. OBJECTIVE: The aim was to study the antiplatelet potential of a series of synthesised 9-phenylxanthene- 3-ones and to find the ideal structural feature(s) for antiplatelet potential and determine the mechanism of action. METHODS: The compounds were synthesized from 1,2,4-triacetoxybenzene and various benzaldehydes. The reaction proceeded smoothly under acidic alcoholic conditions, furnishing the desired products in good yields. The compounds were first screened in whole human blood where platelet aggregation was induced by arachidonic acid. Further analysis was targeted at search of the mechanism of action. RESULTS: Initial screening showed that a majority of the synthesized derivatives had substantial antiplatelet potential. None of the compounds were able to block cyclooxygenase 1 or thromboxane synthase. The mechanism appeared to be based on antagonism of thromboxane effects. The most potent compound 9-(4'-dimethylaminophenyl)-2,6,7-trihydroxy-xanthene-3-one had better potential to block collagen induced platelet aggregation than clinically used acetylsalicylic acid. CONCLUSION: The last mentioned derivative is promising for further in vivo testing.
References provided by Crossref.org
